Reds board & members 'all delighted' with takeover
Cliftonville manager Jim Magilton says that the club's board and members "all seem delighted" with the takeover proposals accepted by the club's membership at an extraordinary general meeting on Wednesday night.
The takeover by Canadian consortium, the Toronto Investment Group (TIG), could see the north Belfast club moving to a full-time model and making improvements to their Solitude home.
Following Wednesday's meeting, a Cliftonville statement said the next stage in the process would involve the club's legal representatives engaging with their counterparts at TIG.
Speaking on Thursday, Magilton said he hasn't "been involved in any of it".
"The club wants to redevelop and I think they're looking forward to that aspect of it," added the Cliftonville boss.
"The competition in the league is so fierce now. Obviously finances does and will help you try and bring maybe a different level of player.
"We'll still go about our business the way we do in terms of recruitment and try and look at the characteristics of the player and that won't change.
"I haven't spoken to anybody from the group, so I won't know that until I'm invited into that conversation."
Magilton added that "somewhere down the line, I [will] get an opportunity to speak to them and see what their vision is".
"Even when I was an outsider looking in, it's a club with massive potential," continued the Reds boss.
"That's brought to the fore with an Irish Cup final, when you see the numbers coming in, the tickets selling so quickly and the redevelopment of the ground etc. It puts Cliftonville on the map."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Posthaste: Canada's work-life balance standing slips globally
Canada has slipped in a worldwide ranking of work-life balance, but still remains well ahead of its southern neighbour. The country ranks seventh on Remote Technology Inc.'s Global Life-Work Balance Index 2025, falling from fifth last year, but is still the only country in the Americas to crack the top 10. Canada's score increased compared to last year, meaning its drop in the rankings is a result of other countries improving. The country scored highly for its statutory sick pay, universal health care and support for LGBTQ+ inclusivity. 'Canadian workplaces tend to value punctuality and dependability, but employees typically maintain a healthy separation between work and family life,' the report said. New Zealand landed in the top spot for the third year in a row, with an index score of 86.87, in part due to a strong minimum wage, happy workers and statutory sick pay. 'Why is New Zealand so life-work-balance-friendly? Well, it helps to be surrounded by such diverse, breathtaking scenery, but while the country doesn't rank at No. 1 for every factor we assessed, it scores consistently well across the study,' the report said. New Zealand and Ireland (81.17) are the only two countries to score above 80 on the ranking; Belgium (75.91), Germany (74.65) and Norway (74.2) rounded out the top five, while Canada's score was 73.46. At the other end of the spectrum, the United States (31.17) ranked 59th of the 60 countries in the report, above only Nigeria (26.67). Still, the report said the U.S.'s low rank can provide opportunity for employers looking to attract talent. 'Statutory provisions for annual leave, sick leave, social security and health care are comparatively low in the U.S.,' the report said. 'That means employers who can provide these benefits as part of an employee-focused (system) will find great success when attracting and retaining top-quality U.S. candidates.' While Canada ranks high globally when it comes to work-life balance, there is certainly some room for improvement. Work has interfered with 32 per cent of Canadians' home and family life, according to a 2024 report by Statistics Canada. The agency also said 33 per cent of Canadians are unable to complete personal tasks at home due to their work commitments. to get Posthaste delivered straight to your road trips to the U.S. from Canada have fallen for the fifth straight month as Canadians look to stay local amid a trade war. Return trips by vehicle among Canadians fell 38.1 per cent in compared to a year ago. More than 2.5 million fewer cars have crossed the border since January compared to the first five months of 2024. Canadians made up more than 25 per cent of visitors to the U.S. last year, but many Canadians are looking to fight back against protectionist U.S. trade policies this year. Read more. Conference of Montreal Day 3 Today's data: Canadian building permits for April, U.S. consumer price index for May Today's earnings: Oracle Corp., Chewy Inc., Victoria's Secret & Co., Dollarama Inc. Canadian businesses trading with U.S. look to 'pivot' as profits decline and expenses rise Bye bye, Beer Stores: Retailer lists 10 additional locations that will close in August Lockheed jet deal to cost Canada more than $27 billion, auditor says Smucker says tariff-fuelled price hikes will weigh on profit For those looking to retire in the next few years and use profits from a home downsizing as a nest egg, be prepared for disappointment when it comes to the exact size of that nest egg. As Jason Heath puts it, Canada's real estate is under pressure and may be for some time, meaning anyone banking on profits from a sale should temper expectations. Read more here. Are you worried about having enough for retirement? Do you need to adjust your portfolio? Are you starting out or making a change and wondering how to build wealth? Are you trying to make ends meet? Drop us a line at wealth@ with your contact info and the gist of your problem and we'll find some experts to help you out while writing a Family Finance story about it (we'll keep your name out of it, of course). Want to learn more about mortgages? Mortgage strategist Robert McLister's Financial Post column can help navigate the complex sector, from the latest trends to financing opportunities you won't want to miss. Plus check his mortgage rate page for Canada's lowest national mortgage rates, updated daily. Visit the Financial Post's YouTube channel for interviews with Canada's leading experts in business, economics, housing, the energy sector and more. Today's Posthaste was written by Ben Cousins with additional reporting from Financial Post staff, The Canadian Press and Bloomberg. Have a story idea, pitch, embargoed report, or a suggestion for this newsletter? Email us at posthaste@ Canada's unemployment rate could reach 7.5% on still strong immigration Canadian businesses showing signs of strain not seen since 2009
Yahoo
32 minutes ago
- Yahoo
Draganfly Announces Pricing of US$13.75 Million Public Offering
Saskatoon, SK., June 11, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) ('Draganfly' or the 'Company'), a drone solutions, and systems developer, today announced the pricing of its public offering (the 'Offering') of 5,500,000 units, with each unit consisting of one common share and one warrant to purchase one common share. Each unit is to be sold at a public offering price of US$2.50, for gross proceeds of approximately US$13.75 million, before deducting placement agent discounts and offering expenses. The warrants will have an exercise price of CA$5.0768 (or US$3.71) per share, are exercisable immediately and will expire five years following the date of issuance. Maxim Group LLC is acting as sole placement agent for the Offering. Draganfly currently intends to use the net proceeds from the Offering for general corporate purposes, including to fund its capabilities to meet demand for its new products including growth initiatives and/or for working capital requirements including the continuing development and marketing of the Company's core products, potential acquisitions and research and development. The Offering is expected to close on or about June 12, 2025, subject to the satisfaction of customary closing conditions. The Offering is subject to customary closing conditions including receipt of all necessary regulatory approvals, including approval of the Canadian Securities Exchange and notification to the Nasdaq Stock Market. The Offering is being made pursuant to an effective shelf registration statement on Form F-10, as amended, (File No. 333-271498) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission ('SEC') on July 5, 2023 and the Company's Canadian short form base shelf prospectus dated June 30, 2023 (the 'Base Shelf Prospectus'). Draganfly will offer and sell the securities in the United States only. No securities will be offered or sold to Canadian purchasers. A preliminary prospectus supplement and accompanying Base Shelf Prospectus relating to the Offering and describing the terms thereof has been filed with the applicable securities commissions in Canada and with the SEC in the United States and is available for free by visiting the Company's profiles on the SEDAR+ website maintained by the Canadian Securities Administrators at or the SEC's website at as applicable. A final prospectus supplement with the final terms will be filed with the securities regulatory authorities in the Canadian provinces of British Columbia, Saskatchewan and Ontario and the SEC. Copies of the preliminary prospectus supplements, accompanying Base Shelf Prospectus, and final prospectus supplement, when available, relating to the Offering may be obtained by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or by telephone at (212) 895-3745 or by email at syndicate@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Draganfly Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A) is a pioneer in drone solutions, AI-driven software, and robotics. With over 25 years of innovation, Draganfly has been at the forefront of drone technology, providing solutions for public safety, agriculture, industrial inspections, security, mapping, and surveying. The Company is committed to delivering efficient, reliable, and industry-leading technology that helps organizations save time, money, and lives. Media Contactmedia@ Company ContactEmail: info@ Forward Looking Statements Certain statements contained in this news release may constitute 'forward-looking statements' or 'forward-looking information' within the meaning of applicable securities laws. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown. In this news release, such forward-looking statements include, but are not limited to, statements regarding the timing, size and expected gross proceeds of the Offering, the satisfaction of customary closing conditions related to the Offering and sale of securities, the intended use of proceeds, and Draganfly's ability to complete the Offering. Closing of the Offering is subject to numerous factors, many of which are beyond Draganfly's control, including but not limited to, the failure of the parties to satisfy certain closing conditions, and other important factors disclosed previously and from time to time in Draganfly's filings with the securities regulatory authorities in the Canadian provinces of British Columbia, Ontario and Saskatchewan and with the SEC. Actual future events may differ from the anticipated events expressed in such forward-looking statements. Draganfly believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and Draganfly is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable securities laws. Investors are cautioned not to unduly rely on these forward-looking statements and are encouraged to read the Offering documents, as well as Draganfly's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR+ at and on EDGAR at in to access your portfolio
Business Wire
an hour ago
- Business Wire
Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP
TORONTO & MONTREAL--(BUSINESS WIRE)--Genesys Capital ('Genesys') is pleased to announce the upcoming closing of Genesys Ventures IV LP ('Fund IV' or the 'fund') to continue its successful track record of building Canadian life science companies in both the medtech and biotech sectors. "Accessing Canadian life sciences investments through a long-term partner like Genesys supports innovation in the market." Genesys welcomes new Limited Partners into Fund IV and thanks returning LP's that engaged early, maintained unwavering support through the fundraising process, and provided catalytic commitments of scale to the fund, in the current context of an unprecedented, ever-changing macro environment. Fund IV institutional investors include: BDC Capital, Export Development Canada (EDC), Fonds de solidarité de la Fédération des travailleurs et travailleuses du Québec (FTQ), HarbourVest, Royal Bank of Canada, Teralys Capital, Venture Ontario, and the Government of Canada's Venture Capital Catalyst Initiative (VCCI), which is administered by BDC Capital under its Life Sciences Stream. Limited Partner commitment to the Genesys franchise and the Genesys investment thesis of co-creating and investing in disruptive Canadian life science opportunities has paid off as Genesys has delivered class leading performance and increasing DPI across its successive funds. Genesys' value-added, partnership approach to working with scientific founders provides both capital and expertise to create companies that compete on a global scale. This has anchored Genesys as a local trusted source of deal flow for global syndicate partners and a first point of contact for repeat entrepreneurs. The team at Genesys has mastered its strategy that takes advantage of the opportunity that the innovation in Canada provides. Genesys has a distinguished history of delivering upper quartile returns across its previous funds and has stepped up into upper decile in its third fund. Notable recent exits include Inversago Pharma, which was acquired by Novo Nordisk for $1.4 billion, and Fusion Pharmaceuticals, which exited to AstraZeneca for $3.3 billion. These successes highlight Genesys' ability to generate fund level returns driven by local Canadian innovation. With this fund, Genesys Capital will continue to set the standard for life sciences venture capital in Canada, with a commitment to building world-class companies and delivering exceptional returns for its investors. Quotes 'EDC is proud to support Genesys Capital, an important funder of companies advancing life sciences in Canada. As healthcare continues its rapid global expansion, Canada stands out with its skilled talent base, early-stage research and development capacity, and strong presence in medtech and biotech. Genesys' approach of building anchor companies will foster enduring ecosystem clusters in Canada, help drive innovation and strengthen Canada's global competitiveness in this growing sector. We look forward to seeing the transformative impact of this fund.' Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC. 'The Fonds de solidarité FTQ's reinvestment in Genesys Capital demonstrates our confidence in a strategic player in life sciences venture capital. With its in-depth knowledge of the Quebec ecosystem and its ongoing support for emerging local companies in biotechnology, Genesys actively contributes to the sector's competitiveness and innovation.' Maxime Pesant, Vice-President, Private Equity and Impact Investing – Life Sciences, at the Fonds de solidarité FTQ. 'Accessing Canadian life sciences investments through a long-term partner like Genesys supports innovation in the market. It is also a strategic move to diversify the Canadian economy and ensure global competitiveness in health and biotechnology, sectors that we believe have historically delivered competitive returns for our investors.' Senia Rapisarda, Managing Director, HarbourVest Partners. 'It is a great time to be investing out of a new fund, and we are looking forward to continuing to create best in class biopharmaceutical and medical technology companies that leverage local innovations.' Damian Lamb, Co-founder and Managing Director, Genesys Capital. 'We are pleased to recommit to the Genesys team and vision. Ontario is recognized as a leader in the life sciences sector and home to some of the sector's most innovative start-ups. The Genesys team, headquartered in Ontario, has a unique ability to identify high-potential companies and support them in becoming global leaders. We are excited about this continued partnership.' Steve Romanyshyn, President and Chief Executive Officer at Venture Ontario. 'Congratulations to the Genesys team. The government's approach of co-investing alongside private VC funds through the Venture Capital Catalyst Initiative is helping boost investment in emerging sectors. Today's announcement shows that Canadian life sciences innovation is going strong and getting the support it needs to compete.' The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. About Genesys Genesys Capital is a Venture Capital Fund based in Toronto, investing in early-stage life sciences opportunities in areas of unmet medical need. With over 25 years of investment experience adhering to a consistent company creation investment strategy, Genesys has become the most successful life sciences venture firm in Canada.
